Iron Deficiency Anemia Therapy Market

Iron Deficiency Anemia Therapy Market & Share Analysis

The global Market is valued at USD 4.5 billion in 2024 and is estimated to grow at a compound annual growth rate (CAGR) of 7.6% from 2024 to 2031. Key market drivers include rising incidence of iron deficiency anemia (IDA) due to poor iron consumption, an incapability of the patient's body to absorb iron, and elderly population.

Key Highlights of the Market

• Increasing prevalence of iron deficiency anemia (IDA) due to increasing due number of individuals diagnosed with iron deficiency anemia (IDA), particularly among populations with chronic kidney diseases.
• Most lucrative products and therapy type in the market are oral iron therapy (which includes products such as Ferrous Sulphate, Ferrous Gluconate, and Ferrous Fumarate) and intravenous iron supplements (which includes Sodium Ferric Gluconate, Iron Carbohydrates, and Ferric Hydroxide)
• In 2024, market is seeing a significant demand for Ferumoxytol, a high-dose intravenous iron supplement. A generic version of Feraheme (Ferumoxytol injection) was launched by Sandoz in June 2021, used for treatment of patients with iron deficiency anemia (IDA) who have an intolerance to oral iron or chronic kidney disease and do not respond in a proper way to oral iron
• North American region is expected to be the most in-demand for iron deficiency and anemia treatment due to rising prevalence of iron deficiency anemia, the presence of well-established healthcare infrastructure, and key market players in the region.

Attributes	Key Insights
Iron Deficiency Anemia Therapy Market Size (2024E)	US$4.5 Bn
Projected Market Value (2031F)	US$7 Bn
Forecast Growth Rate (CAGR 2024 to 2031)	7.6%
Historical Growth Rate (CAGR 2019 to 2023)	7.1%

Market Introduction and Trend Analysis

Iron Deficiency Anemia Therapy Market  are significant global health issues. Iron deficiency and anemia are common health issues that can cause a range of symptoms and require appropriate treatment. Here’s a brief overview of the global scenario of the factors impacting iron deficiency and anemia market

Anaemia: The World Health Organization (WHO) defines anaemia as a condition where the number of red blood cells or their haemoglobin concentration is lower than normal, leading to a reduced capacity of the blood to carry oxygen.

Global Prevalence: Approximately 30% of the global population has iron deficiency anemia, with women and children being the most affected.

Mortality Rates: Research from 1999 to 2018 indicates that the rates of iron deficiency anemia and associated mortality has continued to rise in the United States

Nutritional Causes: The most common nutritional cause of anaemia is iron deficiency, though deficiencies in folate, vitamins B12 and A are also main causes.

Risk Groups: Young kids, menstruating adolescent girls and women, and pregnant and postpartum women are particularly affected by anaemia.

Ethnicity and Age Factors: Americans of non-Hispanic Black lineage are the most likely to develop iron deficiency anemia, and the condition is more prevalent in women and children compared to men.

Historic Growth and Course Ahead

The historical demand for Iron Deficiency Anemia Therapy Market has grown significantly over the years. Anemia was first recognized as a clinical entity in the early 1800s, but it wasn’t until the late 1800s that routine use of the microscope and methods to quantify red blood cell counts, haemoglobin concentration, and haematocrit became common.

In the past, diagnosis and treatment of anemia relied heavily on history and physical examination due to the lack of advanced laboratory tests. The term “anemia” itself first appeared in the English literature in 1807. Over time, with the development of new technologies and a better understanding of iron metabolism, the approach to treating iron deficiency and anemia has become more sophisticated

The future of iron deficiency and anemia treatment is promising, with ongoing research and development of new therapies and strategies. Here are some important points about the advancements in this field:

• Iron Replacement Therapies: New simulations for iron replacement are being explored, including more effective oral iron formulations and intravenous (IV) iron therapies. These aim to improve absorption and reduce gastrointestinal side effects.
• Personalized Treatment: There’s a focus on personalized medicine, where treatments are tailored to individual patient needs, considering factors like the cause of iron deficiency, severity, and response to previous treatments.
• Innovative Administration Methods: Studies suggest that administering iron every other day, instead of daily, can lead to bigger absorption and better patient consequences, especially during pregnancy.
• Addressing Underlying Causes: Alongside iron supplementation, there’s an importance on investigating and managing the underlying causes of iron deficiency to prevent recurrence.
• Patient Blood Management: Identification and management of iron deficiency is becoming a central pillar in patient blood management, ensuring efficient use of resources and improving patient outcomes.

These advancements indicate a shift towards more effective, patient-friendly, and holistic approaches to treating iron deficiency and anemia. As research continues, we can expect further improvements in the management and treatment of these conditions. If you’re interested in more detailed information or specific studies, I can provide summaries or explanations based on the latest research findings.

Iron Deficiency Anemia Therapy Market Growth Drivers

• Rise in Healthcare Expenditure: As healthcare spending grows, it helps in the advance of infrastructure, which in turn supports the expansion of the treatment market. As healthcare spending grows, it supports the improvement of healthcare infrastructure, which in turn facilitates better access to treatments for conditions like iron deficiency and anemia.

Moreover, the rising elderly population and inactive lifestyles are expected to further drive the revenue growth of the market. Due to occurrence of multiple risk factors accounting to the global burden of iron deficiency anemia, there is an increased need for effective treatment options, which is anticipated to propel the market forward during the forecast.

• Increasing consumer awareness: There’s an increasing awareness about iron deficiency anemia screening and management, which is expected to drive the market.
• Improvements in treatment options: Revolutions in treatment are aimed at improving efficacy, minimizing side effects, and enhancing patient adherence.
• Increasing geriatric population: The increasing number of elderly individuals who are more prone to iron deficiency anemia is also a contributing factor.
• Greater prevalence of iron deficiency anemia: With a noteworthy portion of the population, including children and women, affected by anemia, there’s a pressing need for effective treatments.

Factors Impeding the Market

• Shortage of experienced personnel

There is a challenge in the industry due to a lack of skilled healthcare workers, particularly in emerging nations.

• High cost of treatment

The expense associated with iron deficiency anemia treatments can slow down the market’s growth, as it may be unaffordable for many patients.

Future Opportunities for the Iron Deficiency Anemia Therapy Market Companies

New product launches

There’s a growing need for effective treatments, as highlighted by the launch of a generic version of Feraheme by Sandoz in June 2021, and the FDA’s consent of ferric derisomaltose injection in January 2020.

Untapped Markets for Market Growth Potential

Untapped markets in regions like Asia Pacific, Latin America, Middle East, and Africa offer significant growth opportunities due to a large patient pool suffering from iron deficiency anemia

Category-wise Analysis

Parental Iron Therapy is Expected to be dominating the market

Category	Market Share through 2024
Parental Iron Therapy	60%

Parenteral iron therapy has truly made significant developments in the treatment of iron deficiency and anemia. In 2024, it is recognized for its crucial role, particularly in cases where oral iron therapy is not effective or cannot be tolerated. The advancements in parenteral iron formulations have improved their efficacy, tolerability, and safety, making them a valuable option for patients who require iron supplementation.

The impact of parenteral iron therapy on haemoglobin normalization has been documented, highlighting its importance in clinical practice. It’s usually necessary for patients who cannot tolerate or are nonresponsive to oral iron, and in those with chronic diseases where oral iron is poorly absorbed or when rapid iron repletion is desirable.

While oral iron therapy continues to be the universally accepted first-line therapy due to its ease of application, parenteral iron therapy is increasingly being considered for its effectiveness, especially in children with iron deficiency anemia who fail to respond to oral therapy. This shift towards parenteral iron therapy is reflected in its growing market share in the iron deficiency anemia treatment landscape.

The adults segment to exhibit substantial revenue growth

Category	Market Share through 2024
Adults Segment	63.4%

These trends highlight the lucrative opportunities for investment and development in the treatment of iron deficiency and anemia, especially for adults who constitute a significant portion of the affected population.

Treatment usually involves taking iron supplements to increase the low levels of iron in the body and is usually effective. It’s also recommended to eat iron-rich foods like dark-green leafy vegetables, fortified cereals and bread, meat, dried make it harder for the body to absorb iron, such as tea, coffee, milk, dairy, and foods with high levels of phytic acid.

Region-wise Analysis

North America to Dominate the Market

Region	Market Share through 2024
North America	36.56%

North America is an important market for iron deficiency and anemia treatment. The region’s supremacy is attributed to its well-established healthcare infrastructure, high per capita healthcare expenditure, and the presence of key market performers who are increasingly spending in new technologies.

This has contributed to the market’s growth, with North America anticipated to hold 36.56% of the market share in 2024. The U.S. accounts for the majority of this market due to these factors such as rising prevalence of iron deficiency anemia, increasing awareness and apt judgement, improvements in treatment options, and a growing geriatric population.

Competitive Landscape Analysis

The competition landscape in the Iron Deficiency Anemia Therapy Market is quite dynamic, with several key factors influencing its growth and development

North America and Europe continue to regulate the market due to the rising incidence of Iron Deficiency Anemia (IDA) among the older populations. However, the Asia Pacific region is anticipated to witness the fastest growth owing to high population concentration, growing elderly demographic, and rising health awareness

The major companies in the market are involved in various aspects of iron deficiency and anemia therapy, including the development and marketing of oral and intravenous iron therapies, as well as other treatment modalities.

Some of the major activities undertaken by the companies in this are as follows

• Local Production: One key strategy is local manufacturing to reduce operational costs is local production.
• Innovation in Treatment Options: Advancements in treatment options are aimed at improving efficacy, minimizing side effects, and enhancing patient adherence.
• Research and Development: Investment in R&D to create innovative therapies and diagnostic solutions in another important strategy adopted by market players.

Key Industry Developments

March 2024

Cadila Pharmaceuticals announced the launch of an iron supplement injection for the treatment of iron deficiency anemia on March 20, 2024

May 2021

American Regent, Inc. has got approval by the FDA for a single 1000 mg dose option of Injectafer (ferric carboxymaltose injection) for the treatment of iron deficiency anemia in adult patients

June 2021

In June 2021, Sandoz launched a generic version of Feraheme to treat patients with iron deficiency anemia with Ferumoxytol, a high-dose intravenous iron supplement.

Noteworthy companies making significant developments in the industry include Abbvie, Akebia Therapeutics, AMAG Pharmaceuticals, Daiichi Sankyo, Pharmacosmos, Sanofi, Johnson and Johnson, Fresenius, ViforPharma, and Rockwell Medical

Iron Deficiency Anemia Therapy Market Report Scope

Attributes	Details
Forecast Period	2024 to 2031
Historical Data Available for	2019 to 2023
Market Analysis	US$ Million for Value
Key Regions Covered	North America Europe Asia Pacific Latin America The Middle East and Africa
Key Countries Covered	The United States Canada Germany The United Kingdom France China Japan South Korea India Brazil UAE South Africa
Key Market Segments Covered	Product Type Therapy Areas Age Group Formulation Distribution Channel Region
Key Companies Profiled	Akebia Therapeutics, Inc. Bayer AG PHARMACOSMOS A/S Sanofi Johnson & Johnson Services, Inc CSL Vifor AbbVie Inc. (Allergan) Novartis AG Teoxane GSK plc AdvaCare Pharma Apotex Inc. Covis Pharma GmbH
Report Coverage	Market Forecast Company Share Analysis Competition Intelligence DROT Analysis Market Dynamics and Challenges Strategic Growth Initiatives
Customization & Pricing	Available upon request

Iron Deficiency Anemia Therapy Market Segmentation

By Product Type

• Ferrous Sulphate
• Ferrous Gluconate
• Ferrous Fumarate
• Ferric Hydroxide
• Others

By Therapy Areas

• Inflammatory Bowel Disease
• Renal
• Obstetrics and gynaecology
• Congestive heart failure (CHF)
• Oncology
• Other therapy areas

By Age Group

• Adults
• Paediatric
• Geriatric

By Formulation

• Tablets
• Capsules
• Liquids
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

To know more about delivery timeline for this report Contact Sales